Cardiac biomarkers and survival in haemodialysis patients

被引:99
|
作者
Sommerer, C.
Beimler, J.
Schwenger, V.
Heckele, N.
Katus, H. A.
Giannitsis, E.
Zeier, M.
机构
[1] Univ Hosp Heidelberg, Dept Nephrol, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol, D-69120 Heidelberg, Germany
关键词
cardiac biomarker; cardiovascular mortality; haemodialysis; hypervolaemia; NT-proBNP; troponin;
D O I
10.1111/j.1365-2362.2007.01785.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In dialysis patients, cardiac troponin T (cTNT) is often elevated despite the absence of acute myocardial ischaemia, and amino-terminal pro-B-natriuretic peptide (NT-proBNP) is markedly higher compared to non-haemodialysis patients. In a longitudinal observation, we evaluated the association of cTNT and NT-proBNP on cardiovascular morbidity and mortality in haemodialysis patients with and without fluid overload. Materials and methods Plasma cTNT levels of 134 haemodialysis patients were measured before and after a dialysis session by 3rd generation electro-chemoluminiscence immunoassay. NT-proBNP was determined using a polyclonal antibody recognizing the N-terminal fragment of BNP (Elecsys autoanalyzer 2010, Roche Diagnostics, Mannheim, Germany). Volume status was determined by a clinical score system. Cardiovascular morbidity and mortality were assessed over a follow-up period of 36 months. Results Plasma cTNT > 0.03 ng mL(-1) was found in 39.6% of all patients. Patients with hypervolaemia had significantly higher cTNT levels compared to euvolaemic patients (median 0.054 ng mL(-1), interquartile range 0.019-0.153 vs. 0.005 ng mL(-1), < 0.001-0.034; P < 0.001). All haemodialysis patients had excessively high levels of NT-proBNP (median 4524; interquartile range 2000-10 250 pg mL(-1)), and NT-proBNP was significantly higher in hypervolaemic haemodialysis patients (11 988, 5307-19 242) compared to euvolaemic haemodialysis patients (3247, 1619-5574); P < 0.001. Receiver operator curves showed a threshold of cTNT > 0.026 ng mL(-1) and NT-proBNP > 5300 pg mL(-1) as predictors of hypervolaemia. Asymptomatic chronic haemodialysis patients with cTNT > 0.026 ng mL(-1) and NT-proBNP > 5300 pg mL(-1) were more likely to die due to cardiac events in the follow-up period. Multivariate analysis documented that elevated cTNT and NT-proBNP levels were highly predictive for cardiovascular events. Conclusions Plasma levels of cTNT are elevated in approximately 40% and NT-proBNP levels in 100% of asymptomatic chronic haemodialysis patients. Both parameters depend on volume status. Increased NT-proBNP and cTNT are strongly associated with adverse outcome in end-stage renal disease patients undergoing haemodialysis, and are a useful tool for risk stratification in chronic haemodialysis patients.
引用
收藏
页码:350 / 356
页数:7
相关论文
共 50 条
  • [1] Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
    Rasche, Franz Maximilian
    Stoebe, Stephan
    Ebert, Thomas
    Feige, Silvana
    Hagendorff, Andreas
    Rasche, Wilma Gertrud
    Barinka, Filip
    Busch, Volker
    Sack, Ulrich
    Schneider, Jochen G.
    Schiekofer, Stephan
    [J]. BMC NEPHROLOGY, 2017, 18
  • [2] Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
    Franz Maximilian Rasche
    Stephan Stoebe
    Thomas Ebert
    Silvana Feige
    Andreas Hagendorff
    Wilma Gertrud Rasche
    Filip Barinka
    Volker Busch
    Ulrich Sack
    Jochen G. Schneider
    Stephan Schiekofer
    [J]. BMC Nephrology, 18
  • [3] Multiple cardiac biomarkers predict risk of mortality in haemodialysis patients
    Milne, A.
    Millar, C. G.
    Hillis, G. S.
    Cuthbertson, B. H.
    McNeilly, J. D.
    Fazal, M. T.
    Croal, B. L.
    [J]. SCOTTISH MEDICAL JOURNAL, 2007, 52 (02) : 49 - 49
  • [4] Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study
    Jacobs, Leo H.
    van de Kerkhof, Jos J.
    Mingels, Alma M.
    Passos, Valeria Lima
    Kleijnen, Vincent W.
    Mazairac, Albert H.
    van der Sande, Frank M.
    Wodzig, Will K.
    Konings, Constantijn J.
    Leunissen, Karel M.
    van Dieijen-Visser, Marja P.
    Kooman, Jeroen P.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (01) : 243 - 248
  • [5] MODERN PEPTIDE BIOMARKERS AND ECHOCARDIOGRAPHY IN CARDIAC HEALTHY HAEMODIALYSIS PATIENTS
    Rasche, Franz Maximilian
    Stoebe, Stephan
    Ebert, Thomas
    Rasche, Wilma Gertrud
    Schiekofer, Stephan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [6] THE PROGNOSTIC VALUE OF DYSVOLEMIA, CARDIAC BIOMARKERS AND ECHOCARDIOGRAPHIC PARAMETERS IN CHRONIC HAEMODIALYSIS PATIENTS
    Paunic, Zoran
    Dekleva-Manojlovic, Milica
    Markovic-Nikolic, Natasa
    Dimkovic, Nada
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I644 - I644
  • [7] FLUID OVERLOAD IN HAEMODIALYSIS PATIENTS - ASSOCIATION WITH CARDIAC BIOMARKERS, NUTRITIONAL AND INFLAMMATORY STATUS
    Escoli, Rachele
    Luz, Ivan
    Goncalves, Hernani
    Santos, Paulo
    Lobos, Ana Vila
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [8] Biomarkers of Cardiovascular Risk in Haemodialysis Patients
    Franczyk, Beata
    Gluba-Brzozka, Anna
    Rysz, Jacek
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 6086 - 6095
  • [9] Cardiac serum biomarkers in haemodialysis patients: significance of NT-proBNP and troponin in heart
    Leskovar, B.
    Furlan, T.
    Vrtek, K. Vrbinc
    Poznic, S.
    Kosuta, D.
    Adamlje, A.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 325 - 325
  • [10] CARDIAC BIOMARKERS (NT-PROBNP, TROPONIN I) AND HEART FAILURE IN HAEMODIALYSIS PATIENTS
    Garcia Pablos, Nuria
    Salcedo Herrero, David
    Flores Paloma, Maria Paloma
    Palacios Gomez, Maria Eugenia
    Gonzalez, Francisco
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I527 - I527